Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 13/20 | 0.70 |
| ▸ | TK1 | P04183 | 2/20 | 0.53 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | EDNRA | P25101 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | HBB | P68871 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6811658 | 0.89 | PNP (0.58) | PNPTK1HPRT1USP2TSHR | |
| SCHEMBL18249 | 0.82 | PNP (1.00) | PNPTK1 | |
| SCHEMBL9226982 | 0.81 | PNP (0.79) | PNPTK1USP2TSHREDNRA | |
| SCHEMBL3308559 | 0.81 | PNP (0.79) | PNPTK1USP2TSHREDNRA | |
| SCHEMBL1262622 | 0.81 | PNP (0.79) | PNPTK1USP2TSHREDNRA | |
| SCHEMBL1980959 | 0.81 | PNP (0.97) | PNPTK1 | |
| SCHEMBL3310273 | 0.80 | PNP (0.77) | PNPTK1USP2TSHREDNRA | |
| SCHEMBL1533549 | 0.80 | PNP (0.77) | PNPTK1USP2TSHREDNRA | |
| SCHEMBL3021041 | 0.80 | PNP (0.77) | PNPTK1HPRT1USP2TSHR | |
| SCHEMBL3303813 | 0.80 | PNP (0.77) | PNPTK1USP2TSHREDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4054057-B2 | — | — | 2008-02-27 | — | — | JP | claimed |
| EP-0702683-B1 | 06-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER REC TECH LTD (GB) | 2003-09-17 | — | — | EP | claimed |
| CN-1048493-C | 06-substituted guanine derivatives, a process for their prepn. and their use | CANCER RES CAMPAIGN TECH (GB) | 2000-01-19 | — | — | CN | claimed |
| CN-1145622-A | O 6Substituted guanine derivatives, process for their preparation and their use | CANCER RES CAMPAIGN TECH (GB) | 1997-03-19 | — | — | CN | claimed |
| WO-1994029312-A1 | O6-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1994-12-22 | — | — | WO | claimed |
| EP-0374096-A1 | Combination therapy involving 2',3'-dideoxypurine nucleoside and an inhibitor of purine nucleoside phosphorylase, and its compositions | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | claimed |
| US-4772606-A | AUTOIMMUNE DISEASES, ORGAN TRANSPLANTS | WARNER-LAMBERT COMPANY (US) | 1988-09-20 | — | — | US | claimed |
| EP-0178178-A2 | Purine derivatives | WARNER-LAMBERT COMPANY (US) | 1986-04-16 | — | — | EP | claimed |
| US-20220074941-A1 | HSP90 COMBINATION THERAPY | SLOAN KETTERING INST CANCER RES (US) | 2022-03-10 | — | — | US | disclosed |
| EP-2977468-B1 | METHODS OF NOVEL THERAPEUTIC CANDIDATE IDENTIFICATION THROUGH GENE EXPRESSION ANALYSIS IN PULMONARY ARTERIAL HYPERTENSION | VASCULAR BIOSCIENCES INC (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-2977468-A2 | METHODS OF NOVEL THERAPEUTIC CANDIDATE IDENTIFICATION THROUGH GENE EXPRESSION ANALYSIS IN PULMONARY ARTERIAL HYPERTENSION | Vascular Biosciences, Inc. (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20140315929-A1 | HSP90 COMBINATION THERAPY | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-10-23 | — | — | US | disclosed |
| US-20110091421-A1 | Methods of Novel Therapeutic Candidate Identification Through Gene Expression Analysis in Vascular-Related Diseases | VASCULAR BIOSCIENCES, INC. | 2011-04-21 | — | — | US | disclosed |
| EP-0702683-B1 | 06-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER REC TECH LTD (GB) | 2003-09-17 | — | — | EP | disclosed |
| CN-1145622-A | O 6Substituted guanine derivatives, process for their preparation and their use | CANCER RES CAMPAIGN TECH (GB) | 1997-03-19 | — | — | CN | disclosed |
| WO-1994029312-A1 | O6-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1994-12-22 | — | — | WO | disclosed |
| US-5051429-A | For treatment of autoimmune diseases such as arthritis, lupus, antiinflammatory agents, multiple sclerosis, diabetes and viral diseases | WARNER-LAMBERT CO. (US) | 1991-09-24 | — | — | US | disclosed |
| US-4952693-A | TREATING AUTOIMMUNE DISEASES | WARNER-LAMBERT COMPANY (US) | 1990-08-28 | — | — | US | disclosed |
| US-4772606-A | AUTOIMMUNE DISEASES, ORGAN TRANSPLANTS | WARNER-LAMBERT COMPANY (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0178178-A2 | Purine derivatives | WARNER-LAMBERT COMPANY (US) | 1986-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220074941-A1 | HSP90 COMBINATION THERAPY | HSP90AB1, HSP90AB2P, HSP90B1 | PNP 4032/4885TK1 1305/4885HPRT1 2313/4885 |
| US-20140315929-A1 | HSP90 COMBINATION THERAPY | HSP90AB1, HSP90AB2P, HSP90B1 | PNP 4048/4885TK1 1365/4885HPRT1 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.